stoxline Quote Chart Rank Option Currency Glossary
  
Gamida Cell Ltd. (GMDA)
0.0368  -0.022 (-37.84%)    03-28 15:32
Open: 0.0466
High: 0.0492
Volume: 81,844,649
  
Pre. Close: 0.0592
Low: 0.0346
Market Cap: 5(M)
Technical analysis
2024-03-28 3:20:32 PM
Short term     
Mid term     
Targets 6-month :  0.31 1-year :  0.49
Resists First :  0.27 Second :  0.41
Pivot price 0.31
Supports First :  0.03 Second :  0.02
MAs MA(5) :  0.23 MA(20) :  0.32
MA(100) :  0.35 MA(250) :  0.97
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  10.7 D(3) :  23.8
RSI RSI(14): 21.1
52-week High :  2.5 Low :  0.03
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GMDA ] has closed below the lower bollinger band by 14.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ GMDA ] is to continue within current trading range. It is unclear right now based on current values. 116.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.08 - 0.08 0.08 - 0.08
Low: 0.05 - 0.05 0.05 - 0.05
Close: 0.06 - 0.06 0.06 - 0.06
Company Description

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Headline News

Thu, 28 Mar 2024
Gamida Cell Ltd (GMDA) Stock Decreases -90.00% This Week; Should You Buy? - InvestorsObserver

Wed, 27 Mar 2024
Crude Oil Edges Lower; PaySign Shares Spike Higher - Gamida Cell (NASDAQ:GMDA), Direct Digital Holdings ( - Benzinga

Wed, 27 Mar 2024
Gamida Cell to delist as Highbridge takes full ownership - Globes

Wed, 27 Mar 2024
Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript - Seeking Alpha

Wed, 27 Mar 2024
Why Gamida Cell Shares Are Falling Today - TradingView

Wed, 27 Mar 2024
Gamida Cell Ltd. Announces Strategic Restructuring and Privatization - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -54 (M)
Shares Float 0 (M)
Held by Insiders 1.3264e+008 (%)
Held by Institutions 1.2038e+008 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.82
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 680.2 %
Return on Equity (ttm) -41.5 %
Qtrly Rev. Growth 103.7 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.58
Qtrly Earnings Growth -7.591e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -0.05
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 9.98e+006
Forward Dividend 8.86e+006
Dividend Yield 28192100000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android